
Annual report 2022
added 03-16-2023
Trean Insurance Group Net Debt 2011-2026 | TIG
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Trean Insurance Group
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.9 M | -99.2 M | -122 M | -45.2 M | -19.8 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -19.8 M | -122 M | -63.3 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Verastem
VSTM
|
-36.9 M | $ 5.04 | -4.73 % | $ 349 M | ||
|
VistaGen Therapeutics
VTGN
|
-65.6 M | $ 0.57 | -5.87 % | $ 17.6 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Aptinyx
APTX
|
-33.8 M | - | -39.0 % | $ 4.57 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Adaptive Biotechnologies Corporation
ADPT
|
65 M | $ 12.41 | -11.1 % | $ 1.88 B | ||
|
Xenon Pharmaceuticals
XENE
|
-134 M | $ 54.48 | -1.89 % | $ 4.24 B | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | ||
|
Enochian Biosciences
ENOB
|
645 K | - | - | $ 40.5 M | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Summit Therapeutics
SMMT
|
-204 M | $ 16.58 | -3.94 % | $ 12.4 B | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
Alnylam Pharmaceuticals
ALNY
|
-604 M | $ 317.36 | -3.29 % | $ 41.6 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
-107 M | $ 4.29 | -3.6 % | $ 822 M | ||
|
Allakos
ALLK
|
-25 M | - | - | $ 28.6 M | ||
|
Brickell Biotech
BBI
|
-29.7 M | - | -5.38 % | $ 6.06 M | ||
|
Allena Pharmaceuticals
ALNA
|
-29.5 M | - | 3.16 % | $ 1.9 M | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Fusion Pharmaceuticals
FUSN
|
-22.5 M | - | - | $ 1.41 B | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
AlloVir
ALVR
|
-62.7 M | - | 4.14 % | $ 49.1 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
457 M | $ 19.01 | -2.66 % | $ 889 M | ||
|
Gritstone Oncology
GRTS
|
-15.9 M | - | 0.42 % | $ 213 M | ||
|
Завод ДИОД
DIOD
|
-48.6 M | - | - | - | ||
|
Фармсинтез
LIFE
|
612 M | - | - | - | ||
|
ACADIA Pharmaceuticals
ACAD
|
-83 M | $ 20.75 | -3.35 % | $ 3.44 B | ||
|
Aligos Therapeutics
ALGS
|
-132 M | $ 6.66 | -5.4 % | $ 65.8 M | ||
|
Teligent, Inc.
TLGT
|
131 M | - | -13.85 % | $ 16.1 M | ||
|
Viela Bio, Inc.
VIE
|
-130 M | - | - | $ 2.91 B | ||
|
Aravive
ARAV
|
-49.6 M | - | -13.39 % | $ 1.45 M | ||
|
Alkermes plc
ALKS
|
-319 M | $ 29.39 | -1.77 % | $ 4.84 B | ||
|
Cabaletta Bio
CABA
|
-76.6 M | $ 2.68 | -4.96 % | $ 269 M | ||
|
AbbVie
ABBV
|
59.5 B | $ 209.4 | -0.81 % | $ 370 B | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.27 | -2.39 % | $ 977 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Athira Pharma
ATHA
|
-47.2 M | - | - | $ 269 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M |